AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31512024 — intervention group
Group type: COMPARATOR
Intervention: Both UCSD and EBVS
Number of subjects: 100
Study 27760701 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of specialized treatment for a total of five years
Number of subjects: 83
Study 27760701 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation after the standard two-year treatment
Number of subjects: 83
Study 25242460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinless navigation system
Number of subjects: 80
Study 25242460 — intervention group
Group type: COMPARATOR
Intervention: Conventional alignment jigs
Number of subjects: 80
Study 22843310 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using a 980-nm diode-laser at 300 mW for 180 seconds (54 J) applied intraorally and extraorally immediately after surgery and at 24 hours.
Number of subjects: 30
Study 22843310 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LLLT) received only routine management.
Number of subjects: 30
Study 21958233 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week intervention based on social-cognitive constructs including face-to-face sessions, telephone follow-ups, and use of a pedometer
Number of subjects: 92
Study 19456797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 10
Study 19456797 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 17-valerate 0.1% cream
Number of subjects: 10
Study 16863608 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg once daily for 9 months)
Number of subjects: 360
Study 16863608 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 day before procedure and until 9 months follow-up)
Number of subjects: 360
Study 12623291 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap 40 mg
Number of subjects: 665
Study 12623291 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap 120 mg
Number of subjects: 665
Study 12623291 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg
Number of subjects: 665
Study 12623291 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap 40 mg and Tenidap 120 mg
Number of subjects: 665
Study 10837286 — intervention group
Group type: EXPERIMENTAL
Intervention: High isoflavone diet (128.7 mg/d)
Number of subjects: 13
Study 1441728 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A liposome vaccine
Number of subjects: 0
Study 1441728 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of vaccine on the same day in one injection
Number of subjects: 0
Study 1441728 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A virus incorporated into liposomes
Number of subjects: 0
Study 3828091 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (50,000 IU retinol acetate)
Number of subjects: 11
Study 3828091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31714353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS)
Number of subjects: 48
Study 31714353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30464447 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial coil treatment (ECT)
Number of subjects: 6
Study 27585745 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg iron daily (Group A)
Number of subjects: 0
Study 27585745 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg or 0 mg iron daily based on weekly hepcidin screening (Group B)
Number of subjects: 0
Study 27585745 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg or 0 mg iron daily based on weekly hepcidin screening (Group C)
Number of subjects: 0
Study 27585745 — intervention group
Group type: COMPARATOR
Intervention: Universal supplementation (control group not explicitly mentioned)
Number of subjects: 0
Study 24439986 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPT (DAPT plus 3-month cilostazol use, n = 316)
Number of subjects: 630
Study 24439986 — intervention group
Group type: COMPARATOR
Intervention: DAPT (aspirin and clopidogrel for 12 months, n = 314)
Number of subjects: 630
Study 22749688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 0
Study 22749688 — intervention group
Group type: COMPARATOR
Intervention: Internal standard (Propafenone)
Number of subjects: 0
Study 20215553 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI > or = 30 kg/m(2))
Number of subjects: 4381
Study 20215553 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I obese women (BMI 30-34 kg/m(2))
Number of subjects: 4381
Study 20215553 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight status in men
Number of subjects: 4381
Study 20215553 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight women
Number of subjects: 4381
Study 20215553 — intervention group
Group type: COMPARATOR
Intervention: BMI
Number of subjects: 4381
Study 18751649 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program in cognitive-behavioral pain management strategies
Number of subjects: 0
Study 18751649 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15997257 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) therapy for 30 minutes
Number of subjects: 20
Study 15997257 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of paracetamol
Number of subjects: 20
Study 11922547 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine (300 ml)
Number of subjects: 12
Study 11922547 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study 10612504 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol hemihydrate 0.5% solution
Number of subjects: 30
Study 10612504 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate gel 0.5%
Number of subjects: 30
Study 8804673 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg)
Number of subjects: 44
Study 8804673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 1593574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg OD
Number of subjects: 102
Study 1593574 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg OD
Number of subjects: 102
Study 6703982 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbus-based conjunctival flap
Number of subjects: 37
Study 6703982 — intervention group
Group type: COMPARATOR
Intervention: Fornix-based conjunctival flap
Number of subjects: 37
Study 30366971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 109
Study 30366971 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 109
Study 30346543 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based bedside educational intervention; provided for 1 day during inpatient stay
Number of subjects: 97
Study 30346543 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based bedside educational intervention
Number of subjects: 97
Study 27183835 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight leg raise (SLR) tensioner intervention (3 x 1 min)
Number of subjects: 67
Study 24840045 — intervention group
Group type: EXPERIMENTAL
Intervention: Edivoxetine 0.2 mg/kg/day
Number of subjects: 340
Study 24840045 — intervention group
Group type: EXPERIMENTAL
Intervention: Edivoxetine 0.3 mg/kg/day
Number of subjects: 340
Study 24840045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 24840045 — intervention group
Group type: COMPARATOR
Intervention: OROS MPH (18-54 mg/day)
Number of subjects: 340
Study 24840045 — intervention group
Group type: EXPERIMENTAL
Intervention: Edivoxetine 0.1 mg/kg/day
Number of subjects: 340
Study 24840045 — intervention group
Group type: EXPERIMENTAL
Intervention: Edivoxetine treatment
Number of subjects: 340
Study 23180252 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation as the delivery room management default option
Number of subjects: 0
Study 23180252 — intervention group
Group type: COMPARATOR
Intervention: Comfort care as the delivery room management default option
Number of subjects: 0
Study 19556037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - 6 key questions regarding domestic violence (DV)
Number of subjects: 400
Study 19556037 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - 1 question concerning domestic violence (DV)
Number of subjects: 400
Study 19556037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - WC rates
Number of subjects: 400
Study 19556037 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - WC rates
Number of subjects: 400
Study 19556037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - PC rates
Number of subjects: 400
Study 19556037 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - PC rates
Number of subjects: 400
Study 19556037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - psychiatric disorder prevalence
Number of subjects: 400
Study 19556037 — intervention group
Group type: COMPARATOR
Intervention: Non-battered women
Number of subjects: 400
Study 18695931 — intervention group
Group type: EXPERIMENTAL
Intervention: 29.3 mg THC cigarette
Number of subjects: 24
Study 18695931 — intervention group
Group type: EXPERIMENTAL
Intervention: 49.1 mg THC cigarette
Number of subjects: 24
Study 18695931 — intervention group
Group type: EXPERIMENTAL
Intervention: 69.4 mg THC cigarette
Number of subjects: 24
Study 18695931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16169791 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of parents regarding child's asthma history and perceived benefits/barriers to PCP follow-up
Number of subjects: 278
Study 16169791 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent hospitalization, more than one ED visit for asthma in the past year, parent's assessment of 'very severe' asthma, current daily use of a controller medication
Number of subjects: 278
Study 16169791 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental beliefs about the importance of daily asthma medications and understanding causes of asthma attacks
Number of subjects: 278
Study 16169791 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported lack of convenient appointments or prolonged waits in the PCP office
Number of subjects: 278
Study 16169791 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model including clinical factors, parental beliefs, and study intervention
Number of subjects: 278
Study 11962676 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapy with 5‐fluorouracil (5‐FU), leucovorin, and oxaliplatin (L‐OHP)
Number of subjects: 0
Study 11962676 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapy with 5‐FU, leucovorin, and L‐OHP
Number of subjects: 0
Study 10335758 — intervention group
Group type: EXPERIMENTAL
Intervention: AV junction ablation
Number of subjects: 120
Study 10335758 — intervention group
Group type: COMPARATOR
Intervention: Modulation of AV node conduction
Number of subjects: 120
Study 10335758 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study 8926908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg nocte
Number of subjects: 34
Study 8926908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg nocte
Number of subjects: 34
Study 1888829 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole o.m. (n = 12)
Number of subjects: 24
Study 1888829 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole o.m. (n = 12)
Number of subjects: 24
Study 6366419 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 24
Study 6366419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31060890 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 117
Study 31060890 — intervention group
Group type: COMPARATOR
Intervention: Present-Centered Therapy (PCT)
Number of subjects: 117
Study 29769818 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate mouth rinse (CMR)
Number of subjects: 11
Study 29769818 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking to replace all weight loss (DWL)
Number of subjects: 11
Study 29769818 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking 'ad libitum' (DAL)
Number of subjects: 11
Study 27785010 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily
Number of subjects: 182
Study 27785010 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol (IND) 150 μg once daily
Number of subjects: 182
Study 27785010 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrronium (GLY) 50 μg once daily
Number of subjects: 182
Study 27785010 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 μg once daily
Number of subjects: 182
Study 27785010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 27785010 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY)
Number of subjects: 182
Study 24885904 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT) for 16 weeks
Number of subjects: 160
Study 24885904 — intervention group
Group type: COMPARATOR
Intervention: Collaborative assessment and management of suicidality-informed supportive psychotherapy for up to 16 weeks
Number of subjects: 160
Study 24885904 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT)
Number of subjects: 160
Study 24885904 — intervention group
Group type: COMPARATOR
Intervention: Collaborative assessment and management of suicidality-informed supportive psychotherapy
Number of subjects: 160
Study 22225733 — intervention group
Group type: EXPERIMENTAL
Intervention: Central trial coordinator in the Netherlands
Number of subjects: 0
Study 22225733 — intervention group
Group type: COMPARATOR
Intervention: Local study coordinators in Canada
Number of subjects: 0
Study 22225733 — intervention group
Group type: COMPARATOR
Intervention: US sites
Number of subjects: 0
Study 19782267 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate disodium (ATP) at a mean rate of 103 microg/kg/min for 1 hour during reperfusion
Number of subjects: 27
Study 19782267 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 27
Study 19782267 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate disodium (ATP)
Number of subjects: 27
Study 17210507 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower therapy
Number of subjects: 70
Study 17210507 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study 15811926 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human (rh) GH
Number of subjects: 17
Study 15811926 — intervention group
Group type: EXPERIMENTAL
Intervention: ghrelin analog GHRP-2
Number of subjects: 17
Study 15811926 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 17
Study 12234889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilised fluorescein (68 micro g)
Number of subjects: 12
Study 12234889 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluorescein ophthalmic solution (0.17%)
Number of subjects: 12
Study 10805546 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 28
Study 10805546 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 28
Study 8845292 — intervention group
Group type: EXPERIMENTAL
Intervention: 4g MgSO4.7H2O
Number of subjects: 40
Study 8845292 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 40
Study 2353864 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 13
Study 2353864 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin plus gemfibrozil
Number of subjects: 13
Study 7427509 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of early breast cancer
Number of subjects: 2000
Study 31558739 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran supplementation (1-5 g/day)
Number of subjects: 0
Study 31558739 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 27485237 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (20 mg, oral, 3 times daily for 4 weeks)
Number of subjects: 17
Study 27485237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 25885010 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training plus stimulant plus risperidone (augmented treatment)
Number of subjects: 168
Study 25885010 — intervention group
Group type: COMPARATOR
Intervention: Parent training plus stimulant plus placebo (basic treatment)
Number of subjects: 168
Study 24499495 — intervention group
Group type: EXPERIMENTAL
Intervention: NRL001 2 g suppositories (7.5, 10, 12.5 or 15 mg)
Number of subjects: 48
Study 24499495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22034996 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg intravenous ibutilide
Number of subjects: 200
Study 22034996 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 200
Study 19395948 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses LAIV
Number of subjects: 4
Study 19395948 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose LAIV
Number of subjects: 4
Study 19395948 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose LAIV (year 2)
Number of subjects: 4
Study 19395948 — intervention group
Group type: COMPARATOR
Intervention: 2 doses LAIV (year 1)
Number of subjects: 4
Study 19395948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 17595419 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 97
Study 17595419 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness training (FIT)
Number of subjects: 97
Study 17595419 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 97
Study 15649287 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO (40 mg) tablets
Number of subjects: 102
Study 15649287 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C (25 mg) and E (5 mg) tablets
Number of subjects: 102
Study 15649287 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (vehicle only)
Number of subjects: 102
Study 11452938 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) with 10 Gy to the flank at age 4 years
Number of subjects: 2778
Study 11452938 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) with 15-24 Gy at a mean age of 55 months
Number of subjects: 2778
Study 11452938 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) doses under 15 Gy at a mean age of 83 months
Number of subjects: 2778
Study 11452938 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin or cyclophosphamide
Number of subjects: 2778
Study 9855166 — intervention group
Group type: EXPERIMENTAL
Intervention: Arden plate 7 (6.4 cyc/deg)
Number of subjects: 3283
Study 9855166 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance Snellen visual acuity
Number of subjects: 3283
Study 8207741 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril plus hydrochlorothiazide (HCTZ) 12.5 mg once daily
Number of subjects: 524
Study 8207741 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril plus nifedipine SR 10 mg twice daily
Number of subjects: 524
Study 8207741 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo run-in)
Number of subjects: 524
Study 2928444 — intervention group
Group type: EXPERIMENTAL
Intervention: High pleasure
Number of subjects: 40
Study 2928444 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pleasure
Number of subjects: 40
Study 2928444 — intervention group
Group type: EXPERIMENTAL
Intervention: High anger
Number of subjects: 40
Study 2928444 — intervention group
Group type: EXPERIMENTAL
Intervention: Low anger
Number of subjects: 40
Study 810098 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase‐Heparin combination (2,700,000 CTA units of Urokinase and 240 mg of Heparin)
Number of subjects: 120
Study 810098 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (300 mg Heparin)
Number of subjects: 120
Study 810098 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase‐Heparin combination
Number of subjects: 120
Study 31243228 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration insulin glargine (U300G)
Number of subjects: 108
Study 28662708 — intervention group
Group type: EXPERIMENTAL
Intervention: MPCNL
Number of subjects: 150
Study 28662708 — intervention group
Group type: EXPERIMENTAL
Intervention: URSL
Number of subjects: 150
Study 28662708 — intervention group
Group type: EXPERIMENTAL
Intervention: RPLU
Number of subjects: 150
Study 24824157 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient cervical ripening with prostaglandin E2
Number of subjects: 827
Study 24824157 — intervention group
Group type: COMPARATOR
Intervention: Inpatient cervical ripening with prostaglandin E2
Number of subjects: 827
Study 23868083 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain settings ranging from -20 to 20 dB in ultrasound measurements.
Number of subjects: 325
Study 23868083 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for gain setting in the METEOR study sample.
Number of subjects: 325
Study 23868083 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and sex as determinants of gain settings.
Number of subjects: 325
Study 22056739 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with cisplatin (30 mg/m² weekly during RT)
Number of subjects: 230
Study 22056739 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 230
Study 22056739 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 230
Study 19748798 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (eicosapentaenoic acid, 0.96g/day, and docosahexaenoic acid, 0.6g/day)
Number of subjects: 0
Study 19748798 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 0
Study 16569546 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 20